Lantheus (LNTH) announced the appointment of Phuong Khanh Morrow, M.D. to Lantheus’ Board of Directors, effective February 1, 2025. As an independent director, Dr. Morrow will serve as a member of the Board’s Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus’ strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lantheus backs FY24 adjusted EPS view $6.65-$6.70, consensus $6.75
- Lantheus to acquire Evergreen Theragnostics for $250M upfront
- Lantheus to Acquire Evergreen Theragnostics for $250 Million
- Lantheus acquires Evergreen Theragnostics for $250M upfront payment
- Lantheus still sees 2024 EPS $6.65-$6.70, consensus $6.75